On the afternoon of 23rd, the 2021 general meeting of shareholders of Lbx Pharmacy Chain Joint Stock Company(603883) pharmacy was held in Changsha headquarters. After deliberation, all 18 proposals were passed by a high vote.
2021 is a challenging year for the pharmaceutical retail industry. In the face of the complex and changeable environment, Lbx Pharmacy Chain Joint Stock Company(603883) pharmacy achieved steady growth, with annual operating revenue of 15.696 billion yuan, a year-on-year increase of 12.38%, net profit attributable to shareholders of listed companies of 669 million yuan, a year-on-year increase of 7.75%. After retroactive adjustment of the new leasing standards, the net profit attributable to shareholders of listed companies actually increased by 10.10%; The net cash flow from operating activities was 2.298 billion yuan, a year-on-year increase of 58.78%, with strong performance.
At the beginning of this year, local epidemics have occurred in many provinces and cities in China. What impact will it have on the operation of Lbx Pharmacy Chain Joint Stock Company(603883) large pharmacy is a high concern of shareholders at the meeting. The company said that in the first quarter, Xi’an and Shanghai were the areas greatly affected by the epidemic in the company’s layout area, but since this year, the company has rapidly promoted efficient organizational reform and achieved initial results, and its operation execution has been greatly improved from top to bottom. In addition, the company adopted hedging operations such as group purchase and commercial insurance to reduce the impact of the epidemic, and the revenue and profit of Shanghai subsidiary in the first quarter exceeded the budget. From January to March, the year-on-year growth rate of the company’s overall revenue was 8.23%, 13.13% and 20.62% respectively, and the operation was significantly better. Recently, the largest M & A in the history of the company was implemented, and the company controlled the acquisition of Huairen dahealth, a leader in the Western Hunan region. With the subsequent exertion of scale effect and synergy effect of both sides and the continuous deepening of efficient organizational reform of the whole company, the front-line operation ability of the company will be further improved.
Lbx Pharmacy Chain Joint Stock Company(603883) pharmacy has further clarified its regional expansion strategy this year. The company will focus its future strategy on 16 provinces, namely the expansion strategy of “9 + 7”: the development strategy of 9 provinces is self operated franchise and common intensive distribution, the development strategy of 7 provinces is mainly franchise intensive distribution throughout the territory, and self operated is supplemented by o2o and store warehouse integration. In terms of layout, while pursuing “sinking”, the company will also emphasize “improving market share” and improve profitability by expanding the absolute advantage of regional market. The management is full of enthusiasm and confidence for future development.
Since landing on the A-share market in 2015, the company has distributed a total cash dividend of 1.078 billion yuan (including this time), accounting for 106.74% of the net funds raised by listing. According to the profit distribution plan for 2021, the company will distribute a cash dividend of 5 yuan (including tax) for every 10 shares and convert the capital reserve into 3 shares of share capital, with a total dividend of 224 million yuan, accounting for 33.47% of the net profit attributable to the parent company in 2021, the highest in recent four years.
